David C James

List of Publications by Year
in descending order

51 papers	2,439 citations	279798 23 h-index	206112 48 g-index
54 all docs	54 docs citations	54 times ranked	1953 citing authors

#	Article	IF	Citations
1	Control of Recombinant Monoclonal Antibody Effector Functions by Fc N-Glycan Remodeling in Vitro. Biotechnology Progress, 2005, 21, 1644-1652.	2.6	341
2	On the Optimal Ratio of Heavy to Light Chain Genes for Efficient Recombinant Antibody Production by CHO Cells. Biotechnology Progress, 2008, 21, 122-133.	2.6	183
3	Metabolic control of recombinant proteinN-glycan processing in NS0 and CHO cells. Biotechnology and Bioengineering, 2001, 73, 188-202.	3.3	174
4	A mechanistic understanding of production instability in CHO cell lines expressing recombinant monoclonal antibodies. Biotechnology and Bioengineering, 2011, 108, 2434-2446.	3.3	174
5	Engineering mammalian cell factories for improved recombinant monoclonal antibody production: lessons from nature?. Biotechnology and Bioengineering, 2005, 91, 180-189.	3.3	160
6	Metabolic control of recombinant monoclonal antibodyN-glycosylation in GS-NS0 cells. Biotechnology and Bioengineering, 2001, 75, 239-251.	3.3	114
7	Control of Culture Environment for Improved Polyethylenimine-Mediated Transient Production of Recombinant Monoclonal Antibodies by CHO Cells. Biotechnology Progress, 2006, 22, 753-762.	2.6	93
8	Cell lineâ€specific control of recombinant monoclonal antibody production by CHO cells. Biotechnology and Bioengineering, 2010, 106, 938-951.	3.3	90
9	Functional heterogeneity and heritability in CHO cell populations. Biotechnology and Bioengineering, 2013, 110, 260-274.	3.3	88
10	CHO cell line specific prediction and control of recombinant monoclonal antibody Nâ€glycosylation. Biotechnology and Bioengineering, 2013, 110, 2970-2983.	3.3	84
11	Modelâ€<scp>d</scp>irected engineering of â€œdifficultâ€toâ€<scp>e</scp>xpressâ€•monoclonal antibody production by Chinese hamster ovary cells. Biotechnology and Bioengineering, 2014, 111, 372-385.	3.3	79
12	Functional proteomic analysis of GS-NS0 murine myeloma cell lines with varying recombinant monoclonal antibody production rate. Biotechnology and Bioengineering, 2006, 94, 830-841.	3.3	76
13	Systems biotechnology of mammalian cell factories. Briefings in Functional Genomics & Proteomics, 2008, 7, 95-110.	3.8	74
14	Synthetic promoters for CHO cell engineering. Biotechnology and Bioengineering, 2014, 111, 1638-1647.	3.3	60
15	Integrated cell and process engineering for improved transient production of a â€œdifficultâ€toâ€expressâ€œ fusion protein by CHO cells. Biotechnology and Bioengineering, 2015, 112, 2527-2542.	3.3	56
16	Dynamic analysis of GS-NS0 cells producing a recombinant monoclonal antibody during fed-batch culture. Biotechnology and Bioengineering, 2007, 97, 410-424.	3.3	45
17	NFâ€ºB, CRE and YY1 elements are key functional regulators of CMV promoterâ€driven transient gene expression in CHO cells. Biotechnology Journal, 2015, 10, 1019-1028.	3.5	44
18	ACE2-Independent Interaction of SARS-CoV-2 Spike Protein with Human Epithelial Cells Is Inhibited by Unfractionated Heparin. Cells, 2021, 10, 1419.	4.1	39

#	Article	IF	Citations
19	Production of trimeric SARSâ€CoVâ€2 spike protein by CHO cells for serological COVIDâ€19 testing. Biotechnology and Bioengineering, 2021, 118, 1013-1021.	3.3	33
20	Impact of gene vector design on the control of recombinant monoclonal antibody production by chinese hamster ovary cells. Biotechnology Progress, 2011, 27, 1689-1699.	2.6	31
21	Precision control of recombinant gene transcription for CHO cell synthetic biology. Biotechnology Advances, 2016, 34, 492-503.	11.7	29
22	In silico design of context-responsive mammalian promoters with user-defined functionality. Nucleic Acids Research, 2017, 45, 10906-10919.	14.5	29
23	Transcriptomeâ€Based Identification of the Optimal Reference CHO Genes for Normalisation of qPCR Data. Biotechnology Journal, 2018, 13, 1700259.	3.5	25
24	Cell line specific control of polyethylenimineâ€mediated transient transfection optimized with â€œDesign of experimentsâ€•methodology. Biotechnology Progress, 2012, 28, 179-187.	2.6	22
25	Predicting the expression of recombinant monoclonal antibodies in Chinese hamster ovary cells based on sequence features of the CDR3 domain. Biotechnology Progress, 2014, 30, 188-197.	2.6	21
26	An empirical modeling platform to evaluate the relative control discrete CHO cell synthetic processes exert over recombinant monoclonal antibody production process titer. Biotechnology and Bioengineering, 2011, 108, 2193-2204.	3.3	19
27	Whole synthetic pathway engineering of recombinant protein production. Biotechnology and Bioengineering, 2019, 116, 375-387.	3.3	19
28	Importance of Interaction between Integrin and Actin Cytoskeleton in Suspension Adaptation of CHO cells. Applied Biochemistry and Biotechnology, 2016, 178, 1286-1302.	2.9	18
29	A mechanistic dissection of polyethylenimine mediated transfection of CHO cells: To enhance the efficiency of recombinant DNA utilization. Biotechnology Progress, 2014, 30, 1161-1170.	2.6	16
30	Metabolic phenotyping of CHO cells varying in cellular biomass accumulation and maintenance during fedâ€batch culture. Biotechnology and Bioengineering, 2018, 115, 645-660.	3.3	15
31	CHO genome mining for synthetic promoter design. Journal of Biotechnology, 2019, 294, 1-13.	3.8	15
32	A platform for context-specific genetic engineering of recombinant protein production by CHO cells. Journal of Biotechnology, 2020, 312, 11-22.	3.8	14
33	Block decoys: Transcription-factor decoys designed for in vitro gene regulation studies. Analytical Biochemistry, 2013, 443, 205-210.	2.4	13
34	Comparison of dataâ€acquisition methods for the identification and quantification of histone postâ€translational modifications on a Q Exactive HF hybrid quadrupole Orbitrap mass spectrometer. Rapid Communications in Mass Spectrometry, 2019, 33, 897-906.	1.5	13
35	Control of Multigene Expression Stoichiometry in Mammalian Cells Using Synthetic Promoters. ACS Synthetic Biology, 2021, 10, 1155-1165.	3.8	13
36	Highly sensitive detection of mutations in CHO cell recombinant DNA using multiâ€parallel single molecule realâ€time DNA sequencing. Biotechnology and Bioengineering, 2018, 115, 1485-1498.	3.3	12

#	Article	IF	Citations
37	Control of amino acid transport into Chinese hamster ovary cells. Biotechnology and Bioengineering, 2018, 115, 2908-2929.	3.3	12
38	Screening Naturally Occurring Phenolic Antioxidants for Their Suitability as Additives to CHO Cell Culture Media Used to Produce Monoclonal Antibodies. Antioxidants, 2019, 8, 159.	5.1	11
39	High-throughput multiplex analysis of mAb aggregates and charge variants by automated two-dimensional size exclusion-cation exchange chromatography coupled to mass spectrometry. Journal of Chromatography A, 2022, 1670, 462944.	3.7	11
40	Resveratrol addition to Chinese hamster ovary cell culture media: The effect on cell growth, monoclonal antibody synthesis, and its chemical modification. Biotechnology Progress, 2020, 36, e2940.	2.6	9
41	The use of catechins in Chinese hamster ovary cell media for the improvement of monoclonal antibody yields and a reduction of acidic species. Biotechnology Progress, 2020, 36, e2980.	2.6	9
42	Design of synthetic promoters for controlled expression of therapeutic genes in retinal pigment epithelial cells. Biotechnology and Bioengineering, 2021, 118, 2001-2015.	3.3	8
43	High-throughput quantitation of Fc-containing recombinant proteins in cell culture supernatant by fluorescence polarization spectroscopy. Analytical Biochemistry, 2017, 534, 49-55.	2.4	7
44	Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust. Wellcome Open Research, 0, 6, 220.	1.8	6
45	Engineering of the CMV promoter for controlled expression of recombinant genes in HEK293 cells. Biotechnology Journal, 2022, 17, e2200062.	3.5	6
46	Engineering Mammalian Cells for Recombinant Monoclonal Antibody Production. Cell Engineering, 2009, , 153-173.	0.4	5
47	Cell function profiling to assess clone stability. Biotechnology and Bioengineering, 2020, 117, 2295-2299.	3.3	5
48	Constructing Strong Cell Type-Specific Promoters Through Informed Design. Methods in Molecular Biology, 2017, 1651, 131-145.	0.9	4
49	Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust. Wellcome Open Research, 0, 6, 220.	1.8	4
50	Bioinformatic Design of Dendritic Cell-Specific Synthetic Promoters. ACS Synthetic Biology, 2022, , .	3.8	3
51	Risk factors for SARS-CoV-2 seroprevalence following the first pandemic wave in UK healthcare workers in a large NHS Foundation Trust. Wellcome Open Research, 0, 6, 220.	1.8	1